New drug plus standard chemotherapy for advanced neuroendocrine carcinoma
Part of Cancer clinical trials.
This trial tests whether adding a new drug, ZG005, to standard chemotherapy (etoposide and cisplatin) is better than the chemotherapy alone for treating advanced neuroendocrine carcinoma that has not been treated before. The study aims to see if the combination can help people live longer or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a confirmed diagnosis of neuroendocrine carcinoma that has spread or come back.
- You are expected to live more than 3 months.
- You are physically active (ECOG score 0 or 1), meaning you can be up and about, maybe limited in heavy work.
- The cancer has not spread to your brain or the lining of the brain.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (an immunotherapy, a targeted therapy, and a chemotherapy) for advanced neuroendocrine carcinoma. It is designed for people whose cancer has progressed after at least one prior treatment, and aims to see if this combination can help control the cancer.
This study tests a new investigational drug called ZG006 against the chemotherapy your doctor would normally choose for advanced neuroendocrine carcinoma. The trial aims to see if ZG006 works better than standard chemotherapy for people whose cancer has progressed after earlier treatment.
This trial tests a new drug, ZG006, that targets a protein called DLL3 found on some cancer cells. It may be an option for people with small cell lung cancer or neuroendocrine carcinoma who have run out of standard treatments.
This trial tests a new drug (ZG006) for men with advanced neuroendocrine prostate cancer that has progressed after standard platinum-based chemotherapy. The goal is to see if the drug can help slow or shrink the cancer.
This trial tests a new drug (LBL-024) combined with standard chemotherapy for people with advanced EP-NEC, a rare type of neuroendocrine tumor. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a new drug, LBL-024, combined with standard chemotherapy (etoposide and platinum) for people with advanced neuroendocrine carcinoma. The goal is to see if this combination works better than chemo alone.
Hear when a new Neuroendocrine Carcinomas (NEC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.